Blue Jet Healthcare Limited (BLUEJET) - Total Liabilities

Latest as of March 2026: Rs2.81 Billion INR ≈ $30.42 Million USD

Based on the latest financial reports, Blue Jet Healthcare Limited (BLUEJET) has total liabilities worth Rs2.81 Billion INR (≈ $30.42 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Blue Jet Healthcare Limited to evaluate the company's liquid asset resilience ratio.

Blue Jet Healthcare Limited - Total Liabilities Trend (2020–2026)

This chart illustrates how Blue Jet Healthcare Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Blue Jet Healthcare Limited total assets.

Blue Jet Healthcare Limited Competitors by Total Liabilities

The table below lists competitors of Blue Jet Healthcare Limited ranked by their total liabilities.

Company Country Total Liabilities
Ningbo Fujia Industrial Co Ltd
SHG:603219
China CN¥1.27 Billion
Hunan Heshun Petroleum Co Ltd
SHG:603353
China CN¥303.66 Million
Hbt Financial Inc
NASDAQ:HBT
USA $6.03 Billion
FuelCell Energy Inc
NASDAQ:FCEL
USA $274.87 Million
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
China CN¥6.70 Billion
HOB Biotech Group Corp Ltd
SHG:688656
China CN¥86.13 Million
E2open Parent Holdings Inc
NYSE:ETWO
USA $1.48 Billion
Iovance Biotherapeutics Inc
NASDAQ:IOVA
USA $202.66 Million

Liability Composition Analysis (2020–2026)

This chart breaks down Blue Jet Healthcare Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Blue Jet Healthcare Limited balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.21 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Blue Jet Healthcare Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Blue Jet Healthcare Limited (2020–2026)

The table below shows the annual total liabilities of Blue Jet Healthcare Limited from 2020 to 2026.

Year Total Liabilities Change
2026-03-31 Rs2.81 Billion
≈ $30.42 Million
-1.12%
2025-03-31 Rs2.84 Billion
≈ $30.76 Million
+33.14%
2024-03-31 Rs2.14 Billion
≈ $23.10 Million
+18.30%
2023-03-31 Rs1.81 Billion
≈ $19.53 Million
-5.87%
2022-03-31 Rs1.92 Billion
≈ $20.75 Million
-2.35%
2021-03-31 Rs1.96 Billion
≈ $21.25 Million
+13.79%
2020-03-31 Rs1.73 Billion
≈ $18.67 Million
--

About Blue Jet Healthcare Limited

NSE:BLUEJET India Biotechnology
Market Cap
$1.03 Billion
Rs95.52 Billion INR
Market Cap Rank
#8741 Global
#428 in India
Share Price
Rs550.65
Change (1 day)
-3.15%
52-Week Range
Rs327.25 - Rs698.35
All Time High
Rs1010.20
About

Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance… Read more